Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Topical tofacitinib helped a man with severe scalp condition after other treatments failed.

This review discusses telogen effluvium, a common form of hair loss, and reports no new clinical results; the authors outline possible causes, typical prognosis, and management strategies.

In this study, oral tofacitinib was associated with significant hair regrowth in patients with alopecia areata, achieving over 50% reduction in Severity of Alopecia Tool scores, with mild side effects.

This study found that TRF1 plays a crucial role in maintaining pluripotency and stem cell compartments, but it is not a suitable in vivo telomere length marker.

This study found that women with Telogen Effluvium in Thi-Qar Province, Iraq, had significantly lower serum Ferritin and Vitamin D3 levels, suggesting these may contribute to the condition's etiology.

This study reported no significant difference in serum ferritin levels between female patients with telogen effluvium and those without hair loss.

In this case report, a young adult male with resistant alopecia areata showed nearly 90% hair regrowth after 3 months of treatment with tofacitinib, alongside biotin supplementation, without any side effects observed.

This case study reports significant improvements in joint pain and hair regrowth in a 31-year-old female with alopecia universalis, psoriasis vulgaris, and psoriatic arthritis using a combination of tofacitinib and methotrexate after other treatments failed.

This study found that oral tofacitinib significantly reduced alopecia severity and improved quality of life over 12 months for children with moderate to severe alopecia areata, though the authors recommend more research due to the small sample size and absence of a control group.

In this study, researchers found two non-synonymous SNPs in the TERT gene associated with mean wool staple strength in sheep, suggesting TERT as a potential candidate gene for improving wool traits.

This case report describes a young Indian boy with resistant alopecia areata who experienced nearly complete hair regrowth within 5 months of treatment with oral tofacitinib.

This article lists the clinically important interactions and skin reactions of several drugs and substances, including THA, FK506, tamoxifen, tamsulosin, tartrazine, tea tree oil, temazepam, and temozolomide, but provides no new clinical results.

This open-label study found that oral tofacitinib led to significant hair regrowth in patients with moderate-to-severe alopecia areata, supported by changes in gene expression and T cell dynamics.

This study highlights the successful design of recombinant fortilin constructs for potential drug development targeting atherosclerotic plaque formation in cardiovascular disease.

This study found that low ferritin levels are associated with higher telogen ratios in women with diffuse hair loss, suggesting an important role of ferritin in telogen effluvium diagnosis.

Tofacitinib might be used to treat hair loss.

This report describes six cases of hair loss in African American women after switching to tenofovir alafenamide, suggesting it as a possible adverse effect in this population.

In this case report, a young female Indian patient with alopecia areata saw hair regrowth within 2 months of treatment with oral tofacitinib, with continued improvements over a 5-month period and no reported side effects.

This letter to the editor on postpartum telogen effluvium does not include new research findings or data.

This study observed that tofacitinib therapy over about 16 weeks had a positive effect in children with alopecia areata, reducing the SALT index significantly in some patients.

Telogen effluvium is a condition where hair falls out due to various factors like illness, stress, or nutrient deficiency.

In this study, tazarotene 0.1% gel showed greater efficacy than tretinoin 0.025% gel in reducing acne lesions and demonstrated similar efficacy to adapalene 0.1% gel when used less frequently.

In this study, Tithonia diversifolia extract was found to improve certain digestive parameters in crossbred sheep but did not enhance growth performance, as the improvements in digestion did not translate into increased body weight or feed conversion.

A woman developed a severe skin reaction called toxic epidermal necrolysis after taking the antibiotic cephalexin.

In this study, two patients with refractory juvenile dermatomyositis improved clinically and in disease activity after receiving the JAK inhibitor tofacitinib, showing potential effects in managing the condition.

In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

This study found that tofacitinib was an effective and better-tolerated treatment for moderate-to-severe AA compared to SCs, though its efficacy decreased in patients with disease episodes longer than two years.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.